Trial Profile
Reactogenicity and immunogenicity study of two doses of GSK [GlaxoSmithKline] Biologicals' oral live attenuated HRV vaccine [RIX 4414] co-administered with either OPV [poliovirus vaccine live oral] or IPV [poliovirus vaccine inactivated] in healthy infants (approximately 5-10 weeks old) in South Africa
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs RIX 4414 (Primary) ; Hib-DTaP vaccine; Hib-DTaP-poliovirus vaccine; Poliovirus vaccine live oral
- Indications Diphtheria; Haemophilus infections; Pertussis; Poliomyelitis; Rotavirus infections; Tetanus
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 07 Oct 2006 New trial record.